LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 97 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $421,096 | -16.3% | 356,861 | 0.0% | 0.00% | – |
Q2 2023 | $503,173 | +373.6% | 356,861 | +403.8% | 0.00% | – |
Q1 2023 | $106,242 | +28.2% | 70,828 | 0.0% | 0.00% | – |
Q4 2022 | $82,868 | +3.6% | 70,828 | +0.0% | 0.00% | – |
Q3 2022 | $80,000 | -28.6% | 70,827 | 0.0% | 0.00% | – |
Q2 2022 | $112,000 | -82.3% | 70,827 | -82.8% | 0.00% | – |
Q1 2022 | $633,000 | -38.7% | 410,895 | -2.5% | 0.00% | – |
Q4 2021 | $1,032,000 | -3.6% | 421,244 | -0.9% | 0.00% | – |
Q3 2021 | $1,071,000 | -1.5% | 425,009 | +11.5% | 0.00% | – |
Q2 2021 | $1,087,000 | +535.7% | 381,215 | +422.9% | 0.00% | – |
Q1 2021 | $171,000 | +18.8% | 72,899 | -10.9% | 0.00% | – |
Q4 2020 | $144,000 | +94.6% | 81,825 | +3.7% | 0.00% | – |
Q3 2020 | $74,000 | +7.2% | 78,885 | 0.0% | 0.00% | – |
Q2 2020 | $69,000 | -79.7% | 78,885 | -80.8% | 0.00% | – |
Q1 2020 | $340,000 | -22.9% | 410,485 | -17.2% | 0.00% | – |
Q4 2019 | $441,000 | -1.3% | 495,777 | +8.8% | 0.00% | – |
Q3 2019 | $447,000 | – | 455,723 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Defender Capital, LLC. | 5,036,720 | $14,354,000 | 4.77% |
BROADWOOD CAPITAL INC | 34,005,379 | $96,915,000 | 4.33% |
Prescott General Partners LLC | 1,851,851 | $5,278,000 | 0.17% |
Raffles Associates | 43,590 | $124,000 | 0.10% |
Laidlaw Wealth Management LLC | 123,730 | $353,000 | 0.09% |
DCF Advisers, LLC | 74,500 | $212,000 | 0.08% |
Beirne Wealth Consulting Services, LLC | 45,000 | $128,000 | 0.07% |
Strategic Wealth Investment Group, LLC | 64,232 | $183,000 | 0.06% |
Paradigm, Strategies in Wealth Management, LLC | 19,775 | $56,000 | 0.05% |
Fort Sheridan Advisors LLC | 47,931 | $137,000 | 0.05% |